Impact of Decreasing Respiratory Rate on Lung Injury Biomarkers in ARDS Patients

Not Applicable

Completed

• Conditions: Ventilator-Induced Lung Injury; Respiration, Artificial; Acute Respiratory Distress Syndrome
• Interventions: Procedure: Respiratory rate modification

• Registration Number: NCT04641897
• Lead Sponsor: Pontificia Universidad Catolica de Chile

Brief Summary

Acute respiratory distress syndrome (ARDS) is a form of acute lung injury of inflammatory origin, which represents a public health problem worldwide due to its prevalence, and its high mortality rate, close to 40%. Mechanical ventilation is a fundamental therapy to improve gas exchange, however, it can also induce further lung injury, a phenomenon known as ventilator induced lung injury (VILI). The limitation of tidal volume is the strategy that has shown the greatest decrease in mortality and is the cornerstone of protective ventilation. However, the respiratory rate, a fundamental parameter in the programming of the mechanical ventilator, has not been evaluated in most of the main clinical studies to date. Moreover, the natural clinical response to the use of a low tidal volume strategy is the increase in respiratory rate, which may harm the lung as it increases the energy applied to the lung parenchyma. The investigators hypothesize that the use of a lower respiratory rate, tolerating moderate hypercapnia, is associated with less VILI, measured by the release of proinflammatory mediators at the systemic level (biotrauma), compared to a conventional higher respiratory rate strategy in patients with moderate to severe ARDS. This effect is mediated by lower energy applied to the pulmonary parenchyma. To confirm this hypothesis the investigators propose a prospective cross-over clinical trial in 30 adult patients with ARDS in its acute phase, which will be randomized to two sequences of ventilation. Each period will last 12 hours, and respiratory rate (RR) will be set according to PaCO2 goal: 1) Low RR, PaCO2 60-70 mmHg; and 2) High RR, PaCO2 35-40 mmHg.

Protective ventilation will be applied according to ICU standards under continuous sedation and neuromuscular blockade. Invasive systemic arterial pressure and extravascular lung water will be monitored through an arterial catheter (PICCO® system), and airway and esophageal pressures and hemodynamics continuously measured throughout the protocol. The main outcome will be Interleukin-6 in plasma. At baseline and at the end of each period blood samples will be taken for analysis, and electrical impedance tomography (EIT) and transthoracic echocardiography will be registered. After the protocol, patients will continue their management according to ICU standards.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-01
• Study First Submitted: 2020-10-09
• Status Verified: 2020-11
• Study First Submitted QC: 2020-11-18
• Study First Posted: 2020-11-24
• Primary Completion: 2022-02-01
• Study Completion: 2022-02-01
• Last Update Submitted: 2025-01-10
• Last Update Posted: 2025-01-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients intubated and under mechanical ventilation with acute respiratory distress syndrome less than 48 hours

1. Acute onset (less than 1 week)
2. Chest-X-ray: bilateral infiltrates
3. Absence of heart failure or hydrostatic pulmonary edema
4. Oxygenation disorder: PaO2/FiO2 ratio <200, with PEEP ≥5 cmH2O

Exclusion Criteria

• Age <18 years
• Previous chronic respiratory disease (chronic obstructive lung disease, asthma, intersticial lung disease, pulmonary fibrosis, chronic bronchiectasis)
• Hypercapnic respiratory failure, defined as PaCO2 >60 mmHg or pH<7.25 despite a RR >30.
• Concomitant severe metabolic acidosis: pH<7.20
• Catastrophic respiratory failure, defined as PaO2/FiO2 ratio <80, despite optimization of ventilatory parameters, or need for ECMO.
• Contraindication to hypercapnia, such as intracranial hypertension or acute coronary syndrome
• Use of vasoconstrictor drugs in increasing doses in the last 2 hours (≥0.5 μg/kg/min of noradrenaline) or average blood pressure <65mmHg
• Pneumothorax or subcutaneous emphysema, not drained.
• Pregnancy
• Presence of mental or intellectual disability prior to hospitalization
• Early limitation of therapeutic effort

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Sequence A	Respiratory rate modification	Sequence A: Low RR for 12 hours - High RR for 12 hours
Sequence B	Respiratory rate modification	Sequence B: High RR for 12 hours - Low RR for 12 hours.

Primary Outcome Measures

Name	Time	Method
Changes in IL-6	baseline, 12 and 24 hours	levels of IL-6 in plasma

Secondary Outcome Measures

Name	Time	Method
Changes in level of energy applied to the lungs	Baseline, 12 and 24 hours
Changes in transpulmonary driving pressures	Baseline, 12 and 24 hours
Changes in arterials blood gases	Baseline, 12 and 24 hours
Changes overtime in distribution of ventilation	Baseline, 6,12, 24 hours	Distribution of ventilation as assessed by Electrical impedance tomography
Changes in cardiac function and pulmonary edema	Baseline, 12 and 24 hours	measured by PICCO®.
Changes in Auto PEEP	Baseline, 12 and 24 hours
Changes in mean airway pressure	Baseline, 12 and 24 hours
Changes pulmonary edema	Baseline, 12 and 24 hours	measured by PICCO®.

Trial Locations

Locations (1)

Hospital Clinico Universidad Catolica; 🇨🇱 Santiago, Chile